Gene therapy for mitochondrial disorders.

Area of Science:

• Genetics
• Molecular Biology
• Neurology

Background:

• Primary mitochondrial disorders (PMDs) are a heterogeneous group of debilitating genetic diseases.
• Current treatments for PMDs are limited, highlighting the need for novel therapeutic strategies.
• Gene therapy offers a promising avenue for addressing the underlying genetic defects in PMDs.

Purpose of the Study:

• To review the current applications of gene therapy in treating primary mitochondrial disorders.
• To highlight advancements in gene replacement and gene editing technologies for PMDs.
• To discuss the challenges and future directions for clinical translation of gene therapy for PMDs.

Main Methods:

• Review of preclinical studies using recombinant adeno-associated virus (rAAV) vectors for gene replacement in PMD mouse models.
• Analysis of clinical trial data for lenadogene nolparvovec in Leber Hereditary Optic Neuropathy.
• Evaluation of gene editing technologies, including nucleases (TALENs, ZFNs, mitoARCUS) and CRISPR-Cas9, for targeting nuclear and mitochondrial DNA defects.
• Assessment of in vivo delivery methods for gene therapy and gene editing tools.

Main Results:

• Successful preclinical gene replacement in over ten PMD mouse models using advanced rAAV technologies for organ targeting.
• Positive outcomes in Phase 3 clinical trials of lenadogene nolparvovec for Leber Hereditary Optic Neuropathy, demonstrating efficacy and tolerability.
• Advancements in nucleases and CRISPR-based gene editing show potential for treating both nuclear and mitochondrial DNA defects in PMDs.
• In vivo delivery of gene editing tools via rAAV has been successful in mouse models.

Conclusions:

• Gene therapy, particularly using rAAV vectors and gene editing, holds significant therapeutic potential for primary mitochondrial disorders.
• Leber Hereditary Optic Neuropathy is a leading example of successful gene therapy translation, with ongoing clinical trials.
• Overcoming challenges in organ transduction efficiency and optimizing clinical trial design are crucial for broader application of gene therapy in PMDs.